Sermorelin

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino acid human growth hormone-releasing hormone (GHRH). This N-terminal fragment retains full biological activity, as the GHRH receptor-binding domain resides within residues 1-29.

Upon subcutaneous administration, sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, activating adenylyl cyclase through a Gs-protein-coupled mechanism. This increases intracellular cyclic AMP (cAMP), which triggers the synthesis and secretion of growth hormone (GH) in a pulsatile, physiological pattern.

Critically, sermorelin stimulates GH release through the natural hypothalamic-pituitary axis rather than bypassing it. This means the somatostatin-mediated negative feedback loop remains intact — preventing excessive GH accumulation and maintaining normal pulsatile secretion patterns. The resulting GH elevation promotes hepatic IGF-1 production, which mediates the downstream anabolic, metabolic, and regenerative effects associated with growth hormone signalling.

Sermorelin was developed in the 1980s from research characterising the structure of human GHRH, which was first isolated and sequenced in 1982 by two independent groups: Roger Guillemin's team at the Salk Institute and a group at the University of Virginia. The discovery that the first 29 residues retained full biological activity led to the development of sermorelin as a more practical pharmaceutical compound.

Sermorelin was approved by the FDA in 1997 under the brand name Geref for the diagnostic evaluation of pituitary GH secretion capacity and for the treatment of growth hormone deficiency in children. It was one of the first GHRH-based therapies to reach clinical use. Although Geref was voluntarily discontinued in 2008 for commercial reasons (not safety or efficacy concerns), sermorelin remains widely used in compounding pharmacy settings and continues to be studied for anti-aging, body composition, and regenerative applications.